<DOC>
	<DOCNO>NCT00758862</DOCNO>
	<brief_summary>A national , prospective single arm phase II study investigate pharmacokinetics safety 2 % TD1414 cream apply 3 time daily 7 day adult patient impetigo Secondarily Infected Traumatic Lesions ( SITL ) . A total 20 patient enrol .</brief_summary>
	<brief_title>The Pharmacokinetics 2 % TD1414 Cream Adults With Secondarily Infected Traumatic Lesions ( SITL ) Impetigo</brief_title>
	<detailed_description />
	<mesh_term>Impetigo</mesh_term>
	<criteria>Ability willingness comply study requirements/procedures Age ≥ 18 ≤65 year Primary bullous/nonbullous impetigo SITL Patients suffer primary bullous/nonbullous impetigo must : Not 10 discrete lesion , A total lesional area ≥ 1 cm2 ≤ 100 cm2 , Any surround erythema must extend beyond 2 cm edge lesion , Total SIRS score equal ≥ 8 Patients suffer SITL must : A total infected area traumatic lesion ≥ 1 cm2 ≤ 100 cm2 , Any surround erythema must extend beyond 2 cm edge lesion , Total SIRS score ≥ 8 , SITL cause burn animal/human bite Amenable treatment topical antibiotic alone Body Mass Index ≥18 ≤ 35 kg/m2 . Immunosuppressed state serious systemic disease Signs and/or symptom systemic infection , malaise fever local adenopathy fever Unwillingness abstain use topical product include emollient lesional area study Systemic treatment antibacterial immunosuppressive agent ( e.g . corticosteroid ) within 2 day day 1 ( inhaled/intranasal steroid may use ) Topical treatment antibacterial , immunosuppressive agent ( e.g . corticosteroid ) antiseptic ( e.g . alcohol , chlorhexidine , hydrogen peroxide , iodine ) lesional area within 2 day day 1 Indication surgical systemic treatment SITL/impetigo Known suspect hypersensitivity component study medication Participation interventional clinical trial use investigational drug within 30 day 5 halflives ( whichever longer ) prior day 1 Previously enrol study A blood alcohol content ≥ 0.08 % determined Breathalyzer test Known suspect history alcohol abuse/alcoholism drug abuse Known suspect impairment liver function Heart rhythm disturbance clinically significant quantitative qualitative abnormality pretreatment ECG Blood donation excess 500mL within 56 day day 1 donation study within 3 day leave study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>